Research analysts covering NORTHWEST BIOTHERAPEUTICS.
Recent press releases and 8-K filings for NWBO.
Northwest Biotherapeutics Secures $5 Million Convertible Note Financing
NWBO
Debt Issuance
New Projects/Investments
Convertible Preferred Issuance
- On November 14, 2025, Northwest Biotherapeutics, Inc. entered into a $5 million convertible Promissory Note financing with YA II PN, Ltd..
- The proceeds from this financing are designated for construction and equipment costs for the first Grade C manufacturing suite in its Sawston, UK facility, as well as for ongoing Company operations.
- The Note has a 12-month term, includes a five percent Original Issue Discount, and carries no interest.
- It is convertible at the holder's option, with monthly conversion amounts limited to approximately one fifth of the total unless the conversion price is above $0.29.
Nov 20, 2025, 9:26 PM
Northwest Biotherapeutics Completes Acquisition of Advent BioServices
NWBO
M&A
New Projects/Investments
- Northwest Biotherapeutics, Inc. (NWBio) has closed its acquisition of Advent BioServices Ltd. (Advent), which is now a wholly owned subsidiary of NWBio.
- The acquisition includes Advent's fixed assets, intellectual property, and other intangibles.
- NWBio is not issuing any shares or other securities for the acquisition; instead, 19 million NWBio securities (13.5 million shares and 5.5 million options) previously issued to Advent are reverting back to NWBio.
- The consideration for the acquisition includes a payment of £1.4 million and the net amount of accounts payable, to be paid in installments over two years, with payments commencing 90 days after the October closing.
Oct 30, 2025, 8:40 PM
Northwest Biotherapeutics Acquires Advent BioServices Ltd.
NWBO
M&A
New Projects/Investments
- Northwest Biotherapeutics (NWBio) closed its acquisition of Advent BioServices Ltd. on October 24, 2025, making Advent a wholly owned subsidiary of NWBio.
- The acquisition is expected to enhance operational efficiencies and scale-up capabilities, including integrating technologies, streamlining supply chain management, and facilitating manufacturing capacity.
- The consideration for the acquisition includes a payment of £1.4 million and the net amount of accounts payable due from NWBio to Advent, payable in installments over two years.
- As part of the acquisition, 19 million NWBio securities (13.5 million shares and 5.5 million options) previously issued to Advent are reverting back to NWBio.
Oct 24, 2025, 4:03 PM
Northwest Biotherapeutics to Acquire Advent BioServices
NWBO
M&A
New Projects/Investments
- Northwest Biotherapeutics has entered into an agreement to acquire Advent BioServices Ltd., which is expected to enable the Company's operations to become fully integrated, enhance its positioning for scale-up, and yield important synergies and cost savings.
- As part of the acquisition, 19 million NWBio securities (13.5 million shares and 5.5 million options) that were previously issued to Advent will revert back to the Company.
- The consideration for the acquisition includes a payment of £1.4 million and the net amount of accounts payable, to be paid in installments over two years beginning 90 days after the acquisition agreement.
Aug 27, 2025, 4:39 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more